Seasonal Influenza – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions.

Seasonal influenza, commonly referred to as “the flu”, is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of the flu include fever, cough, sore throat, runny or stuffy nose, body aches, fatigue, headaches, and sometimes vomiting or diarrhea, especially in children. The flu virus spreads primarily through respiratory droplets when an infected person coughs, sneezes, or talks. It can also spread by touching a surface or object contaminated with the virus and then touching the mouth, nose, or eyes.

The Seasonal Influenza drugs in development market research report provide comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Influenza and features dormant and discontinued products.


* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Seasonal Influenza
Key Targets
· Hemagglutinin HA; Hemagglutinin; Neuraminidase; 2019 Novel corona Virus Spike Glycoprotein; Envelope Protein M; Neuraminidase A; Polymerase Basic Protein 2; Substance P Receptor; Toll Like Receptor 2; and RNA Polymerase
Key Mechanisms of Action
· Toll Like Receptor 2 Agonist; Toll-Like Receptor 6 Agonist; Neuraminidase Inhibitor; Polymerase Basic Protein 2 Inhibitor; RNA Polymerase Inhibitor; Sirtuin Activator; Substance P Receptor Agonist; Envelope Protein M Inhibitor; and Hemagglutinin Inhibitor
Key Routes of Administration
· Intramuscular; Oral; Inhalational; Nasal; Parenteral; Intradermal; Intravenous; Subcutaneous; and Transdermal
Key Molecule Types
· mRNA Vaccine; Subunit Vaccine; Inactivated Vaccine; Small Molecule; Vaccine; Monoclonal Antibody; Recombinant Vector Vaccine; Antibody; Blood Derivative; and Monoclonal Antibody Conjugated
Major Companies
· Moderna Inc; Novavax Inc; Ocugen Inc; BioNTech SE; Vaxart Inc; Vaxess Technologies Inc; Vaxxas Pty Ltd; University of Wisconsin Madison; Viramatix Sdn Bhd; and VLP Therapeutics LLC


  • Therapeutics in Development: Covering 63 molecules, with 57 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Seasonal Influenza therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Seasonal Influenza pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Seasonal Influenza treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Adimmune Corp
BioNTech SE
Centivax Inc
CHA Vaccine Institute Co Ltd
Cidara Therapeutics Inc
Cilian AG
Clover Biopharmaceuticals Ltd
Cocrystal Pharma Inc
ContraFect Corp
Curevac NV
Dynavax Technologies Corp
ENA Respiratory Pty Ltd
Etna Biotech Srl
Evrys Bio
Expres2ion Biotechnologies ApS
FluGen Inc
Georgia State University
GreenLight Biosciences Holdings PBC
GSK plc
Invivyd Inc
iosBio Pharma Ltd
Jiangsu Kangrun Biological Technology Co Ltd
LiteVax BV
Longhorn Vaccines and Diagnostics LLC
Medigen Vaccine Biologics Corp
Mercia Pharma Inc
Moderna Inc
Mynvax Pvt Ltd
New Amsterdam Sciences Inc
Novavax Inc
Ocugen Inc
Respana Therapeutics Inc
SAB Biotherapeutics Inc
Scientific Research Institute for Biological Safety Problems
Seqirus Ltd
Sinovac Biotech Ltd
SiVEC Biotechnologies LLC
Sumitomo Pharma Co Ltd
Sunomix Therapeutics
TechnoVax Inc
Tehran University of Medical Sciences
The Institute of Vaccines and Medical Biologicals
The University of British Columbia
University of Wisconsin Madison
Vaxart Inc
Vaxess Technologies Inc
Vaxxas Pty Ltd
Viramatix Sdn Bhd
VLP Therapeutics LLC
XBiotech Inc
Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage


Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones




Secondary Research

Primary Research

Expert Panel Validation

Contact Us



List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024


List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Seasonal Influenza – Drugs In Development, 2024 in real time.

  • Access a live Seasonal Influenza – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.